MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

The Medicines Company Company Profile (NASDAQ:MDCO)

Consensus Ratings for The Medicines Company (NASDAQ:MDCO) (?)
Ratings Breakdown: 3 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Buy (Score: 2.70)
Consensus Price Target: $36.56 (8.67% upside)

Current Analysts' Coverage Summary for The Medicines Company (NASDAQ:MDCO)
Show:
DateFirmActionRatingPrice TargetActions
8/28/2015Jefferies GroupUpgradeHold -> Buy$29.00 -> $43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/17/2015Leerink SwannBoost Price TargetOutperform$35.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/29/2015GuggenheimReiterated RatingBuy$42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/10/2015OppenheimerReiterated RatingSector PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/6/2015MizuhoUpgradeNeutral -> Buy$28.00 -> $41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/2/2015RBC CapitalReiterated RatingBuy$39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015JPMorgan Chase & Co.Boost Price TargetOverweight$31.00 -> $32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/16/2015Citigroup Inc.Set Price TargetHold$30.00 -> $32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/20/2014Credit SuisseUpgradeNeutral -> Outperform$27.00 -> $33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/23/2014Bank of AmericaLower Price TargetBuy -> Neutral$37.00 -> $27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2014Piper JaffrayDowngradeOverweight -> Neutral$41.00 -> $29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 8/29/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha